S2 Genomics, a leading manufacturer of tissue sample preparation systems for single cell genomics assays, has announced that it has raised $16 million in Series A funding. The funding comes from BroadOak Capital Partners and Research Corporation Technologies (RCT) and will play a crucial role in accelerating the commercial adoption of S2 Genomics’ Singulator platform.
The Singulator platform, which utilizes single-use cartridges, allows for reproducible, rapid, and automated tissue dissociations into single cell or nuclei suspensions. Neuroscience and oncology researchers widely use these suspensions to advance their studies.
Since its launch in 2020, the Singulator platform has gained significant traction among prestigious academic research organizations, pharmaceutical companies, biotech companies, and service providers worldwide. The platform includes a user-friendly benchtop instrument, single-use consumables, and a library of over 80 validated protocols for sample preparation from various tissue types.
The new funding from BroadOak Capital Partners and RCT will not only expand S2 Genomics’ customer base but also enable the development of new applications for the Singulator platform. Jonathan Schimmel, CEO of S2 Genomics, expressed excitement about the partnership, recognizing the valuable expertise that both investors bring to the table.
Anup Parikh, Operating Partner of BroadOak Capital Partners, also voiced his enthusiasm for collaborating with S2 Genomics and its accomplished team. He highlighted the Singulator platform’s ability to address scalability challenges in single cell genomics and make single cell applications more accessible to a wider customer base.
The significant funding secured by S2 Genomics will propel the commercialization of the Singulator platform, opening up new possibilities for single cell genomics research. With their dedication to providing innovative solutions in the life sciences field, S2 Genomics continues to play a crucial role in advancing scientific discoveries.
FAQ:
1. What is S2 Genomics?
S2 Genomics is a leading manufacturer of tissue sample preparation systems for single cell genomics assays.
2. What is the Singulator platform?
The Singulator platform is a system developed by S2 Genomics that utilizes single-use cartridges to enable reproducible, rapid, and automated tissue dissociations into single cell or nuclei suspensions.
3. How is the Singulator platform used in research?
The Singulator platform is widely used in neuroscience and oncology research to provide researchers with the necessary tools for advancing their studies.
4. What is the significance of the recent funding secured by S2 Genomics?
S2 Genomics has secured $16 million in Series A funding from BroadOak Capital Partners and Research Corporation Technologies (RCT). This funding will support the company’s efforts to accelerate the commercial adoption of the Singulator platform and develop new applications.
5. Who are the investors behind the funding?
The funding comes from BroadOak Capital Partners and Research Corporation Technologies (RCT).
6. How has the Singulator platform performed since its initial launch?
The Singulator platform has experienced significant success since its launch in 2020. It has been adopted by academic research organizations, pharmaceutical companies, biotech companies, and service providers worldwide.
7. What does the Singulator platform consist of?
The Singulator platform consists of a user-friendly benchtop instrument, single-use consumables, and a library of over 80 validated protocols for sample preparation from various tissue types.
8. How will the funding aid S2 Genomics?
The funding will not only expand S2 Genomics’ customer base but also allow for the development of new applications for the Singulator platform.
9. What expertise do BroadOak Capital Partners and RCT bring to the partnership?
BroadOak Capital Partners and RCT bring valuable expertise in driving commercial growth and addressing scalability challenges in single cell genomics.
10. How does S2 Genomics contribute to scientific discoveries?
S2 Genomics’ commitment to providing innovative solutions in the field of life sciences positions them as a key player in advancing scientific discoveries through their Singulator platform.
Key Terms:
– Single cell genomics: A field of genomics that involves studying the genetic information of individual cells.
– Tissue sample preparation systems: Systems used to prepare tissue samples for analysis in scientific research.
– Series A funding: The first round of funding for a startup company, typically provided by venture capitalists.
– Reproducible: Able to be repeated and obtain similar results.
– Rapid: Quick or fast.
– Automated: Performed automatically by a machine or system, without human intervention.
– Dissociation: The process of separating cells or tissues into individual components.
– Nuclei suspensions: Samples containing isolated cell nuclei.
– Neuroscience: The scientific study of the nervous system, including the brain and spinal cord.
– Oncology: The branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
– Pharmaceutical companies: Companies that research, develop, and produce pharmaceutical drugs.
– Biotech companies: Companies that use biological processes to develop products or technologies.
– Service providers: Organizations that offer specialized services in a particular industry or field.
– Benchtop instrument: An instrument or device that is small enough to be used on a laboratory bench.
– Protocols: Step-by-step instructions or procedures for performing a specific task or experiment.
– Commercialization: The process of bringing a product or technology to the commercial market.
Suggested Related Links:
– S2 Genomics website
– BroadOak Capital Partners
– Research Corporation Technologies
The source of the article is from the blog toumai.es